Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial - PubMed
5 hours ago
- #bacterial vaginosis
- #live biotherapeutic
- #Lactobacillus crispatus
- LACTIN-V, a live biotherapeutic product containing Lactobacillus crispatus CTV-05, significantly reduced recurrent bacterial vaginosis (BV) in a phase 2b trial, though efficacy was incomplete.
- By week 12, an L. crispatus-dominant vaginal microbiota was achieved in 30% of LBP recipients vs. 9% of placebo recipients, primarily due to CTV-05, with native L. crispatus strains also increasing over time.
- Inflammatory cytokines decreased after metronidazole treatment in both groups but returned to baseline in placebo recipients.
- Successful L. crispatus colonization was associated with pre-treatment microbiota, baseline inflammation, post-treatment bacterial load, and clinical/behavioral variables, informing improved intervention strategies.